Showing results (1-10 of 30) with videos related to
Sort By:
Pageof 3
Anticancer Research|January 10, 2014
Standardization of chemotherapy and individual dosing of platinum compoundsFlorent Puisset, Antonin Schmitt, Etienne ChatelutMedicinal Research Reviews|May 22, 2019
Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicityMarie-Noëlle Paludetto, Florent Puisset, Etienne Chatelut, et al.Clinical Pharmacokinetics|January 11, 2023
Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical PracticeFélicien Le Louedec, Florent Puisset, Etienne Chatelut, et al.CPT: Pharmacometrics & Systems Pharmacology|August 3, 2021
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayrFélicien Le Louedec, Florent Puisset, Fabienne Thomas, et al.British Journal of Clinical Pharmacology|June 21, 2005
Dexamethasone as a probe for vinorelbine clearanceFlorent Puisset, Florence Dalenc, Etienne Chatelut, et al.Journal of Medicinal Chemistry|August 14, 2018
Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic MetabolitesMarie-Noëlle Paludetto, Christian Bijani, Florent Puisset, et al.Cancers|January 8, 2023
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal CancerFlorent Puisset, Mourad Mseddi, Loïc Mourey, et al.Journal of Pharmaceutical and Biomedical Analysis|March 24, 2018
Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MSMarie-Noëlle Paludetto, Florent Puisset, Félicien Le Louedec, et al.Cancer Chemotherapy and Pharmacology|January 10, 2020
Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearanceMelanie White-Koning, Marie Noëlle Paludetto, Félicien Le Louedec, et al.Cancer Chemotherapy and Pharmacology|February 15, 2021
Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidinesMaud Maillard, Audrey Eche-Gass, Mony Ung, et al.Pageof 3